- Ticker
- ADMA
- Price
- 3.85
- Stock movement down
- -0.11 (-2.78%)
- Company name
- ADMA Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 850.48M
- Ent value
- 960.44M
- Price/Sales
- 3.92
- Price/Book
- 5.60
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 35.00
- PEG
- -
- EPS growth
- -
- 1 year return
- 21.84%
- 3 year return
- 28.37%
- 5 year return
- -5.47%
- 10 year return
- -
Last updated: 2023-11-27
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 16, 2023
iO Charts is a Seeking Alpha partner
ADMA Biologics, Inc. is undervalued based on long-term potential and now is free cash flow positive. Read more about ADMA stock here.
November 9, 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADMA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.92 |
| Price to Book | 5.60 |
| EV to Sales | 4.42 |
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Head, Business...
November 9, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 8, 2023
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 220.90M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 217.09M |
| Gross profit (TTM) | 46.70M |
| Operating income (TTM) | -63.35M |
| Net income (TTM) | -104.68M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | 0.11 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 21.51% |
| Operating margin (TTM) | -29.18% |
| Profit margin (TTM) | -48.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 86.52M |
| Net receivables | 15.51M |
| Total current assets | 270.40M |
| Goodwill | 3.53M |
| Intangible assets | 1.01M |
| Property, plant and equipment | 58.26M |
| Total assets | 348.46M |
| Accounts payable | 13.23M |
| Short/Current long term debt | 154.44M |
| Total current liabilities | 39.27M |
| Total liabilities | 196.49M |
| Shareholder's equity | 151.97M |
| Net tangible assets | 151.97M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -98.35M |
| Capital expenditures (TTM) | 20.69M |
| Free cash flow (TTM) | -119.05M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -68.88% |
| Return on Assets | -30.04% |
| Return on Invested Capital | -68.47% |
| Cash Return on Invested Capital | -77.87% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.95 |
| Daily high | 3.95 |
| Daily low | 3.82 |
| Daily Volume | 1.25M |
| All-time high | 12.49 |
| 1y analyst estimate | 5.13 |
| Beta | 0.87 |
| EPS (TTM) | -0.53 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ADMA | S&P500 | |
| Current price drop from All-time high | -69.18% | -4.86% |
| Highest price drop | -91.27% | -56.47% |
| Date of highest drop | 11 Oct 2021 | 9 Mar 2009 |
| Avg drop from high | -59.30% | -11.47% |
| Avg time to new high | 104 days | 13 days |
| Max time to new high | 2263 days | 1805 days |
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 7, 2023
iO Charts is a Seeking Alpha partner
ADMA Biologics, specializes in plasma-derived biologics, had 77% Q2 2023 revenue increase. Read more about ADMA stock here.
August 26, 2023
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
850.48M
Marketcap category
Small-cap
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Employees
0
Investor relations
-
SEC filings
CEO
Adam S. Grossman
Country
USA
City
Ramsey
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director,...
August 10, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
August 9, 2023
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
August 8, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
July 19, 2023
There are fundamental, sentimental and valuation facts to suggest ADMA is mispriced in my opinion. ADMA stock is rated as a buy. Explore more here.
June 16, 2023
Today, we take a deeper look at ADMA Biologics, whose stock has doubled over the past year thanks to robust sales growth. Click for more on ADMA stock.
June 15, 2023
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director,...
May 11, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 10, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 9, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 2, 2023
ADMA Biologics recently reported their Q4 and Full-Year 2022 earnings, which revealed a beat on EPS and revenue. Check out my updated game plan for ADMA stock.
March 29, 2023
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director of...
March 24, 2023
iO Charts is a Seeking Alpha partnerNext page